Page results
-
More than 800 patients on waiting lists for Ear, Nose and Throat appointments across North Central London seen in two days during ENT surgery ‘super-weekend’
-
A UCLH clinician scientist has won a prestigious international award for his groundbreaking work on how tumours evolve, which is helping to explain why cancer treatments sometimes fail and paving the way for more precise, personalised therapies.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
Patient information for Red Cell Network patients
-
UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.
-
Alison Clements, head of operations, patient flow and EPRR, has received a medal in recognition of her work to support NHS preparations for the Coronation of Charles III and Camilla last May.
-
Young cancer patients and staff couldn’t believe their eyes when David Beckham paid a visit to the University College Hospital Macmillan Cancer Centre earlier this year.
-
Patient information who have been recommended to use a Biatain® dressing on your skin that has broken down due to your radiotherapy or proton beam therapy treatment.
-
UCLH and Whittington Health have a long history of working together to benefit patients, staff and our communities across Camden, Haringey, Islington and beyond. This includes services such as the virtual ward, orthopaedic surgery and paediatric dentistry.
-
UCLH has treated the first brain cancer patient with immunotherapy prior to standard treatment as part of a pioneering trial.
File results
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services
-
FOI/2022/0226 - Treatments for Haemophilia A
-
FOI/2022/0227 - Number of cancer trackers and cancer MDT co-ordinators at Trust
-
FOI/2022/0230 - Fabry, Gaucher and Pompe diseases drug treatments
-
FOI/2022/0232 - Number of patients who have died while waiting for elective care
-
FOI/2022/0233 - Diagnosis/ treatment of epilepsy, dravet syndrome, lennox gastaut syndrome and tuberous sclerosis complex